Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$15.70 -0.3%	$14.37	$9.57 ▼ $30.41	$2.17B	0.96	1.53 million shs	1.23 million shs
CURLF Curaleaf	$0.84 +6.5%	$0.87	$0.68 ▼ $4.45	$558.26M	0.59	630,876 shs	295,190 shs
NAMS NewAmsterdam Pharma	$19.75 -2.3%	$18.29	$14.06 ▼ $27.29	$2.22B	-0.03	688,898 shs	2.45 million shs
RXRX Recursion Pharmaceuticals	$5.00 +1.6%	$4.91	$3.79 ▼ $12.36	$2.03B	0.84	15.09 million shs	26.97 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-0.25%	-5.25%	-0.06%	+3.97%	-39.24%
CURLF Curaleaf	+6.52%	-3.95%	+1.01%	-13.83%	-79.01%
NAMS NewAmsterdam Pharma	-2.28%	-2.03%	+4.61%	-16.56%	+2.92%
RXRX Recursion Pharmaceuticals	+1.63%	-6.89%	+9.65%	-21.75%	-46.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.6403 of 5 stars	3.4	1.0	3.4	2.8	2.5	0.0
CURLF Curaleaf	2.2299 of 5 stars	3.5	2.0	0.0	2.4	0.0	1.3
NAMS NewAmsterdam Pharma	2.9903 of 5 stars	3.5	2.0	0.0	2.6	5.0	0.0
RXRX Recursion Pharmaceuticals	1.9384 of 5 stars	3.2	1.0	0.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	178.43% Upside
CURLF Curaleaf	3.00	Buy	$6.25	642.72% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$43.00	117.72% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	40.00% Upside

Current Analyst Ratings Breakdown

Latest CURLF, ARWR, NAMS, and RXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00
5/6/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00
4/10/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$10.00 ➝ $8.00
4/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00

(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$545.21M	3.98	N/A	N/A	$1.54 per share	10.19
CURLF Curaleaf	$1.35B	0.41	$0.09 per share	9.57	$1.64 per share	0.51
NAMS NewAmsterdam Pharma	$47.14M	47.04	N/A	N/A	$3.50 per share	5.64
RXRX Recursion Pharmaceuticals	$59.82M	33.98	N/A	N/A	$1.98 per share	2.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	N/A	N/A	-236.60%	-64.09%	8/6/2025 (Estimated)
CURLF Curaleaf	-$281.20M	-$0.31	N/A	N/A	N/A	-14.82%	-13.67%	-4.58%	N/A
NAMS NewAmsterdam Pharma	-$176.94M	-$1.88	N/A	N/A	N/A	N/A	N/A	N/A	8/6/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$328.07M	-$1.77	N/A	N/A	N/A	-579.52%	-76.56%	-55.68%	8/6/2025 (Estimated)

Latest CURLF, ARWR, NAMS, and RXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/8/2025	Q1 2025	CURLF Curaleaf	-$0.07	-$0.07	N/A	-$0.08	N/A	N/A
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
5/5/2025	Q1 2025	RXRX Recursion Pharmaceuticals	-$0.44	-$0.50	-$0.06	-$0.50	$18.12 million	$14.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CURLF Curaleaf	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	7.27	6.09	6.09
CURLF Curaleaf	0.85	1.11	0.51
NAMS NewAmsterdam Pharma	N/A	10.61	10.61
RXRX Recursion Pharmaceuticals	0.04	4.35	4.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
CURLF Curaleaf	0.03%
NAMS NewAmsterdam Pharma	89.89%
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
CURLF Curaleaf	N/A
NAMS NewAmsterdam Pharma	20.84%
RXRX Recursion Pharmaceuticals	8.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	120.68 million	Optionable
CURLF Curaleaf	5,600	663.41 million	N/A	Not Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	74.37 million	Optionable
RXRX Recursion Pharmaceuticals	400	406.50 million	329.18 million	Optionable

CURLF, ARWR, NAMS, and RXRX Headlines

Recent News About These Companies

Recursion Pharmaceuticals (NASDAQ:RXRX) Given New $5.00 Price Target at Morgan Stanley

June 17 at 2:46 AM | americanbankingnews.com

Expert Outlook: Recursion Pharmaceuticals Through The Eyes Of 4 Analysts

June 17 at 2:33 AM | benzinga.com

Morgan Stanley Lowers Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target to $5.00

June 16 at 12:03 PM | marketbeat.com

Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?

June 16 at 6:03 AM | fool.com

Leerink Partnrs Issues Positive Estimate for RXRX Earnings

June 15 at 1:45 AM | americanbankingnews.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 2.2% - Here's Why

June 13, 2025 | marketbeat.com

Leerink Partnrs Has Positive Estimate for RXRX Q2 Earnings

June 13, 2025 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 2.4% - Should You Sell?

June 12, 2025 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 4% Higher - Should You Buy?

June 11, 2025 | marketbeat.com

Insmed surges on lung drug data; Recursion cuts staff

June 11, 2025 | biopharmadive.com

AI-Focused Recursion Pharmaceuticals Stock Jumped 31% Last Week; Here's Why

June 11, 2025 | talkmarkets.com

Recursion to lay off 20% of workforce amid biotech funding woes

June 11, 2025 | msn.com

Recursion: Lack Of Near-Term Catalysts Leaves The Stock Vulnerable

June 11, 2025 | seekingalpha.com

Recursion lays off 20% of staff in wake of pipeline cutbacks

June 10, 2025 | fiercebiotech.com

Recursion Pharmaceuticals Stock Is Up 10% Today: What's Happening?

June 10, 2025 | benzinga.com

Recursion Pharmaceuticals: Recent Readouts Disappointing, Future Readouts Risky

June 10, 2025 | seekingalpha.com

Recursion Pharma to reduce workforce by 20%

June 10, 2025 | msn.com

Recursion Pharmaceuticals (RXRX) Jumps 31% On Next-Gen AI

June 10, 2025 | msn.com

Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday

June 10, 2025 | fool.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 4.9% Higher - Should You Buy?

June 10, 2025 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Large Volume Increase - Here's What Happened

June 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CURLF, ARWR, NAMS, and RXRX Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$15.70 -0.04 (-0.25%)

Closing price 06/16/2025 04:00 PM Eastern

Extended Trading

$15.70 +0.01 (+0.03%)

As of 06/16/2025 05:55 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Curaleaf OTCMKTS:CURLF

$0.84 +0.05 (+6.52%)

As of 06/16/2025 03:59 PM Eastern

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.

NewAmsterdam Pharma NASDAQ:NAMS

$19.75 -0.46 (-2.28%)

Closing price 06/16/2025 04:00 PM Eastern

Extended Trading

$19.98 +0.23 (+1.18%)

As of 06/16/2025 06:24 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Recursion Pharmaceuticals NASDAQ:RXRX

$5.00 +0.08 (+1.63%)

Closing price 06/16/2025 04:00 PM Eastern

Extended Trading

$4.93 -0.07 (-1.40%)

As of 06/16/2025 08:00 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time